Why the study?
The study was conducted to evaluate the efficacy and safety of captopril, simvastatin, and L-carnitine as cardioprotective therapies on echocardiographic, electrocardiographic, lipid, and vascular parameters in children with type 1 diabetes mellitus.
Do captopril, simvastatin, or L-carnitine improve echocardiographic parameters, lipid profiles, and cardiac biomarkers in children with type 1 diabetes mellitus?
Do captopril, simvastatin, or L-carnitine improve echocardiographic parameters, lipid profiles, and cardiac biomarkers in children with type 1 diabetes mellitus?
Captopril, simvastatin, and L-carnitine improve surrogate markers of cardiac function in children with type 1 diabetes, with simvastatin and L-carnitine additionally improving lipid profiles.
Supports adjunctive cardioprotection in pediatric T1DM; extends adult surrogate data to children.
OBJECTIVES: To assess the efficacy and safety of captopril, simvastatin, and L-carnitine as cardioprotective drugs in children with type 1 diabetes mellitus on different echocardiographic parameters, electrocardiographic parameter, lipid profile, and carotid intima-media thickness. METHODS: This randomised controlled trial was conducted on 100 children with type 1 diabetes mellitus for more than 3 years during the period from September 2018 to June 2020. Fifty healthy children of matched age and sex served as a control group. The patients were randomly assigned into four groups (25 children each): no-treatment group who received no cardioprotective drug, simvastatin group who received simvastatin (10-20 mg/day), captopril group who received captopril (0.2 mg/kg/day), and L-carnitine group who received L-carnitine (50 mg/kg/day) for 4 months. Lipid profile, serum troponin I, carotid intima-media thickness, and echocardiographic examinations were performed on all included children before and after the treatment. RESULTS: Total cholesterol and low-density lipoprotein were significantly decreased in children who received simvastatin or L-carnitine. Triglycerides significantly decreased only in children who received simvastatin. High-density lipoprotein significantly increased in simvastatin and L-carnitine groups only. Serum troponin I decreased significantly in all the three treatment groups. Carotid intima-media thickness showed no significant change in all treatment groups. Echocardiographic parameters significantly improved in simvastatin, L-carnitine, and captopril groups. CONCLUSION: Captopril, simvastatin, and L-carnitine have a significant beneficial effect on cardiac functions in children with type 1 diabetes mellitus. However, only simvastatin and L-carnitine have a beneficial effect on the lipid profile. The drugs were safe and well tolerated.Clinical trial registration: The clinical trial was registered at www.clinicaltrial.gov (NCT03660293).
No takes yet. Share an insight, caveat, or question.
Badreldeen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: